Kenvue Inc (KVUE)

Currency in USD
16.85
-0.08(-0.46%)
Real-time Data·
High dividend Yield
KVUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.7016.88
52 wk Range
14.0225.17
Key Statistics
Prev. Close
16.93
Open
16.85
Day's Range
16.7-16.88
52 wk Range
14.02-25.17
Volume
4.3M
Average Vol. (3m)
40.78M
1-Year Change
-25.88%
Book Value / Share
5.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KVUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.33
Upside
+14.74%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Kenvue Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Kenvue Inc Company Profile

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Kenvue Inc SWOT Analysis


Valuation Insights
Analysts set average price target of $23.20, with estimates ranging from $18 to $29, reflecting diverse views on Kenvue's growth potential and market challenges
Strategic Shift
Delve into Kenvue's new management initiatives, focusing on operational simplification and innovation to drive growth and address underperformance in key segments
Financial Headwinds
Kenvue faces challenges across all segments, with revised 2025 outlook projecting low-single-digit declines in organic sales, down from previous growth estimates
Tylenol Turmoil
Explore the impact of acetaminophen controversy on Kenvue's market position and the potential long-term implications for its flagship brand
Read full SWOT analysis

Kenvue Inc Earnings Call Summary for Q2/2025

  • Q2 2025 adjusted EPS of $0.29 missed expectations by 17.14%, revenue of $3.84B fell short by 8.13%
  • Stock rose 1.45% pre-market despite earnings miss; organic sales declined 4.2% in Q2
  • Full-year 2025 guidance: organic sales to decline low single digits, adjusted EPS projected at $1.00-$1.05
  • Company focusing on largest brands, innovation, and operational efficiency amid cautious consumer sentiment
  • Considering strategic alternatives to streamline operations; 83% of U.S. business holding or gaining market share
Last Updated: 08/07/2025, 01:11 PM
Read Full Transcript

Compare KVUE to Peers and Sector

Metrics to compare
KVUE
Peers
Sector
Relationship
P/E Ratio
22.5x27.6x11.8x
PEG Ratio
0.640.090.03
Price / Book
3.0x2.5x1.5x
Price / LTM Sales
2.1x1.8x0.9x
Upside (Analyst Target)
9.3%42.8%21.4%
Fair Value Upside
Unlock17.9%12.0%Unlock

Analyst Ratings

3 Buy
11 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 19.33
(+14.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold18.00+6.76%17.00MaintainNov 10, 2025
RBC Capital
Hold21.00+24.56%22.00MaintainNov 04, 2025
Canaccord Genuity
Hold17.00+0.83%15.00MaintainNov 04, 2025
Canaccord Genuity
Hold15.00-11.03%-DowngradeOct 29, 2025
Evercore ISI
Hold18.00+6.76%-MaintainOct 28, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.75%
Dividend Yield
4.90%
Industry Median 2.72%
Annualized Payout
0.83
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 03, 2025
EPS / Forecast
0.28 / 0.26
Revenue / Forecast
3.76B / 3.83B
EPS Revisions
Last 90 days

KVUE Income Statement

People Also Watch

216.91
VRSK
-1.96%
220.33
SNDK
-3.57%
158.70
PI
+0.28%
66.09
FISV
-0.29%
219.89
AMD
+0.88%

FAQ

What Is the Kenvue (KVUE) Stock Price Today?

The Kenvue stock price today is 16.85

What Stock Exchange Does Kenvue Trade On?

Kenvue is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Kenvue?

The stock symbol for Kenvue is "KVUE."

Does Kenvue Pay Dividends? What’s The Current Dividend Yield?

The Kenvue dividend yield is 4.9%.

What Is the Kenvue Market Cap?

As of today, Kenvue market cap is 32.22B.

What Is Kenvue's Earnings Per Share (TTM)?

The Kenvue EPS (TTM) is 0.75.

When Is the Next Kenvue Earnings Date?

Kenvue will release its next earnings report on Feb 05, 2026.

From a Technical Analysis Perspective, Is KVUE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Kenvue Stock Split?

Kenvue has split 0 times.

How Many Employees Does Kenvue Have?

Kenvue has 22000 employees.

What is the current trading status of Kenvue (KVUE)?

As of Dec 08, 2025, Kenvue (KVUE) is trading at a price of 16.85, with a previous close of 16.93. The stock has fluctuated within a day range of 16.70 to 16.88, while its 52-week range spans from 14.02 to 25.17.

What Is Kenvue (KVUE) Price Target According to Analysts?

The average 12-month price target for Kenvue is USD19.33333, with a high estimate of USD23 and a low estimate of USD17. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +14.74% Upside potential.

What Is the KVUE After Hours Price?

KVUE's last after hours stock price is 16.86, the stock has decreased by -0.07, or -0.41%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.